Similar articles

• Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

  Serrate C, Loriot Y, De La Motte Rouge T, Gross-Goupil M, Massard C, Escudier B, Bossi A, Fizazi K. Serrate C, et al. Ann Oncol. 2009 May;20(5):965. doi: 10.1093/annonc/mdp112. Ann Oncol. 2009. PMID: 19403938 No abstract available.
• Commentary on "Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel." Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D, Department of Oncology, Rambam Medical Center, Haifa, Israel.: Prostate 2014 Apr;74(4):433-40; doi:10.1002/pros.22765. [Epub 2013 Dec 11].

  Trump D. Trump D. Urol Oncol. 2016 May;34(5):247. doi: 10.1016/j.urolonc.2015.02.008. Epub 2015 Apr 20. Urol Oncol. 2016. PMID: 25907623
• A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.

  Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK; Prostate Cancer Clinical Trials Consortium. Ross RW, et al. Cancer. 2008 Feb 1;112(3):521-6. doi: 10.1002/cncr.23195. Cancer. 2008. PMID: 18085595 Clinical Trial.
• [Castration resistant prostate cancer 2011].

  Miller K. Miller K. Aktuelle Urol. 2011 Mar;42(2):95-102. doi: 10.1055/s-0031-1271399. Epub 2011 Mar 24. Aktuelle Urol. 2011. PMID: 21437832 Review. German.
• Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs.

  Rizzo M. Rizzo M. Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188481. doi: 10.1016/j.bbcan.2020.188481. Epub 2020 Nov 17. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33217485 Review.